Jamie Koufman, MD, from the Voice Institute of New York discusses proton pump inhibitors—their&nbsp;adverse effects, alternatives, and more.</p>
Jamie Koufman, MD, from the Voice Institute of New York discusses proton pump inhibitors—their&nbsp;adverse effects, alternatives, and more.</p>
Jamie Koufman, MD, from the Voice Institute of New York discusses proton pump inhibitors—their&nbsp;adverse effects, alternatives, and more.</p>
Daniel Einhorn, MD, from Scripps Whittier Diabetes Institute talks about the "debate of 2018": ACP's new guidance on controlling HbA1c levels in adults with diabetes.
Daniel Einhorn, MD, from Scripps Whittier Diabetes Institute talks about the "debate of 2018": ACP's new guidance on controlling HbA1c levels in adults with diabetes.
Daniel Einhorn, MD, from Scripps Whittier Diabetes Institute talks about the "debate of 2018": ACP's new guidance on controlling HbA1c levels in adults with diabetes.
Daniel Einhorn, MD, from Scripps Whittier Diabetes Institute talks about the "debate of 2018": ACP's new guidance on controlling HbA1c levels in adults with diabetes.
Dr Seth Baum interviews Dr Mikhail Kosiborod about clinical trial data surrounding the possible mechanisms of action of SLGT2 inhibitors for heart failure, as well as the cardio-renal connection.
Dr Seth Baum interviews Dr Mikhail Kosiborod about clinical trial data surrounding the possible mechanisms of action of SLGT2 inhibitors for heart failure, as well as the cardio-renal connection.
Dr Seth Baum interviews Dr Mikhail Kosiborod about clinical trial data surrounding the possible mechanisms of action of SLGT2 inhibitors for heart failure, as well as the cardio-renal connection.
